Viewing Study NCT02356458

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:04 AM
Ignite Modification Date: 2026-02-11 @ 9:10 PM
Study NCT ID: NCT02356458
Status: TERMINATED
Last Update Posted: 2022-03-11
First Post: 2015-02-02
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Sponsor: Swiss Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mantle Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Mantle cell lymphoma View
None Relapsed View
None Refractory View
None Cancer View
None Lymphoma View
None Ibrutinib Imbruvica View
None Bortezomib Velcade View